Direct assays for adrenal steroids in neonates
As one of the approved SAS Laboratories for l7-hydroxyprogesterone (17-0HP) we have Letters 117 followed with interest the recent correspondence in Annals. In particular, we would endorse the views expressed'< by the Glasgow group: that while direct 17-0HP assays are of value in neonatal screening programmes, all elevated results from direct methods should be checked by methods incorporating solvent-extraction. The measurement of 17-0HP in sick infants is, however, totally different. First, such infants tend to be dehydrated, sampling is difficult, volumes of plasma are small, and results are required urgently. Thus processing by both direct and with-extraction methods is rarely possible. Secondly, the results in such infants, even using a well-validated with-extraction procedure, often fall outside normal range values, if these are defined as the range in healthy full-term infants. What is required are data from appropriate reference populations including those from sick neonates, of known gestational age, at various times after birth, who are subsequently confirmed not to have an inherited enzyme defect. Put simply, how high can a 17-0HP result be in a sick premature infant without CAH being present? A formal inter-laboratory collaboration between laboratories using cross-validated techniques is necessary to acquire a sufficient data-base. Inclusion of results from direct assays, which have a marked positive-bias in this subject group, can only complicate a sufficiently difficult task. While Dr Bodlaender! refers to an evaluation by Makela and Ellis of the revised direct DPC assay which incorporates a more specific antibody, his informal second-hand report cannot provide the basis for informed judgement; this must await publication of the full paper. The earlier paper by these authors, evaluating the original direct DPC assay, was excellent and contained the essential detailed account of the reference population. We see little point in establishing separate neonatal reference ranges for both direct and extraction assays: if the direct protocol is inaccurate it should not be used. The major justification for a direct assay is the ability to devolve the test to less specialized laboratories. In view of the difficulties of interpreting equivocal results in sick premature infants it would appear preferable to maintain this assay in a limited number of reference centres so that experience of variation in the neonatal population can be more efficiently acquired.
Letters
We agree with the Glasgow group that it is advisable to confirm the diagnosis of CAH by a urinary steroid profile. However, we can not agree with the opinion expressed" by Drs Honour and Brook that the urinary steroid profile is reliable in the diagnosis of 21-hydroxylase deficiencies. In our experience, when plasma 17-0HP results have been equivocal due to prematurity and/or stress, the urinary profiles have been judged to be abnormal, but no decision on congenital versus development causation of the abnormality has been possible, due again to a lack of data from a suitable reference population. Also, no biochemical assay will answer the question 'Is it a boy or a girl?' The appropriate sex of rearing will be a question of clinical judgement, of the likely better outcome following medical and surgical intervention. The genotype and biochemical parameters are relevant but not determining factors in this decisionmaking process. 
